Conference Details - Overview
Continuing Education Information
Physicians: Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.This activity is approved for AMA PRA Category 1 Credit™
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.
Critical Advances in the Management of Immune Thrombocytopenic Purpura
San Francisco Marriott
San Francisco, CA
December 5, 2008
Conference Overview
Treatment standards for immune/idiopathic thrombocytopenic purpura (ITP) have not dramatically changed in the past 10 years. The Critical Advances in the Management of Immune Thrombocytopenic Purpura symposium will address significant advances in ITP therapy, specifically the application of thrombopoietin receptor agonists. An overview of the pathophysiology of ITP will set the stage for case-based lectures. An initial case presentation will review current treatment standards for patients with newly diagnosed ITP, and subsequent case presentations will feature discussions of new therapeutic options in ITP and address treatment recommendations for splenectomized, nonsplenectomized, and refractory patients. A debate will be held on 2 treatment opinions for a patient with refractory ITP following steroid therapy in order to contrast different options and the relative merits and drawbacks of each and will be followed by an opportunity for audience interaction via a moderated question-and-answer session with the entire faculty serving on the panel.
This activity is supported by an educational donation provided by Amgen.
This educational program is directed toward medical oncologists and hematologists. Nurses, physician assistants, fellows, and pharmacists in oncology who are interested in the treatment of hematologic malignancies are also invited to attend. At the conclusion of this symposium, you should be able to:
- Evaluate current standards of care for patients with newly diagnosed ITP
- Outline the pathophysiology of ITP
- Identify the appropriate patient population to receive thrombopoietin receptor agonists and when in the disease course to begin treatment
- Appraise the safety and efficacy of long-term therapy with thrombopoietin receptor agonists in splenectomized and nonsplenectomized patients with ITP
- Summarize monitoring options for patients with ITP receiving thrombopoietin receptor agonists
- Describe quality-of-life issues facing patients with ITP receiving thrombopoietin receptor agonists